Published in Mol Cancer Res on March 02, 2010
Therapy-induced senescence in cancer. J Natl Cancer Inst (2010) 2.45
Aurora kinase inhibitors as anticancer molecules. Biochim Biophys Acta (2010) 1.33
Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene (2013) 1.21
Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. EMBO Mol Med (2012) 1.10
Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther (2015) 0.99
Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas. Cell Cycle (2012) 0.94
Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clin Cancer Res (2012) 0.94
Depletion of Aurora A leads to upregulation of FoxO1 to induce cell cycle arrest in hepatocellular carcinoma cells. Cell Cycle (2013) 0.92
Cell death signaling and anticancer therapy. Front Oncol (2011) 0.91
Aurora kinase A in gastrointestinal cancers: time to target. Mol Cancer (2015) 0.90
Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Invest New Drugs (2014) 0.90
Decreased skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer. Transl Oncol (2012) 0.88
Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. Cancer Res (2014) 0.85
Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition. Mol Biol Cell (2015) 0.85
Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: implications for stem cell mitosis and centrosome dynamics. Stem Cell Res (2014) 0.85
A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3. Cell Cycle (2013) 0.85
Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice. EMBO J (2015) 0.84
p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther (2015) 0.81
NEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner. Mol Cancer Res (2014) 0.81
A Cell Biologist's Field Guide to Aurora Kinase Inhibitors. Front Oncol (2015) 0.80
Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment. J Natl Cancer Inst (2015) 0.78
Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines. PLoS One (2014) 0.78
Mitotic Kinases and p53 Signaling. Biochem Res Int (2012) 0.78
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. Invest New Drugs (2015) 0.78
Update on aurora kinase inhibitors in gynecologic malignancies. Recent Pat Anticancer Drug Discov (2008) 0.77
The Aurora kinase inhibitors in cancer research and therapy. J Cancer Res Clin Oncol (2016) 0.76
RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy. Oncol Lett (2016) 0.76
Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation. Sci Rep (2016) 0.75
The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation. Oncotarget (2016) 0.75
Aurora kinase A is not involved in CPEB1 phosphorylation and cyclin B1 mRNA polyadenylation during meiotic maturation of porcine oocytes. PLoS One (2014) 0.75
Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer. Mol Cancer Ther (2016) 0.75
Modelling conservation in the Amazon basin. Nature (2006) 9.07
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature (2009) 8.44
Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet (2005) 3.28
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A (2007) 3.27
The Steap proteins are metalloreductases. Blood (2006) 2.37
Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res (2011) 2.35
Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity. Cancer Res (2007) 1.62
Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res (2004) 1.49
The mitochondrial ATP-binding cassette transporter Abcb7 is essential in mice and participates in cytosolic iron-sulfur cluster biogenesis. Hum Mol Genet (2006) 1.47
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res (2004) 1.42
Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sections. J Histochem Cytochem (2009) 1.38
CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes. J Immunol (2006) 1.25
Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. Cancer Cell (2012) 1.19
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A (2003) 1.14
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer (2012) 1.06
Multimodal imaging with (18)F-FDG PET and Cerenkov luminescence imaging after MLN4924 treatment in a human lymphoma xenograft model. J Nucl Med (2011) 1.01
Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma. PLoS One (2007) 0.98
The binocular advantage in visuomotor tasks involving tools. Iperception (2013) 0.96
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol (2010) 0.92
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Cancer Res (2010) 0.92
PDGF C is a selective alpha platelet-derived growth factor receptor agonist that is highly expressed in platelet alpha granules and vascular smooth muscle. Arterioscler Thromb Vasc Biol (2004) 0.91
Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237). Drug Metab Lett (2014) 0.90
Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma (2010) 0.87
A mammal-specific exon of WT1 is not required for development or fertility. Mol Cell Biol (2002) 0.87
Identification of a lung cancer cell line deficient in atg7-dependent autophagy. Autophagy (2015) 0.87
Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Cancer Chemother Pharmacol (2013) 0.84
Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma. Br J Haematol (2012) 0.82
MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma. Mol Cancer Ther (2012) 0.80
Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905). J Med Chem (2011) 0.80
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Ther (2005) 0.79
Effects of video placement and spatial context presentation on path reconstruction tasks with contextualized videos. IEEE Trans Vis Comput Graph (2008) 0.75
Message from the paper chairs and guest editors. IEEE Transactions on Visualization and Computer Graphics. IEEE Trans Vis Comput Graph (2014) 0.75
Two Models to Conduct Nonphysician-led Exercise Stress Testing in Low to Intermediate Risk Patients. Crit Pathw Cardiol (2017) 0.75
Message from the Editor-in-Chief and from the Associate Editor-in-Chief. IEEE Trans Vis Comput Graph (2019) 0.75
3D user interfaces. IEEE Comput Graph Appl (2014) 0.75